Conv. Plasma
Nigella Sativa

All vitamin D studies
Meta analysis
study COVID-19 treatment researchVitamin DVitamin D (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Hospitalization 13% Improvement Relative Risk Vitamin D for COVID-19  Israel et al.  Prophylaxis Is prophylaxis with vitamin D beneficial for COVID-19? Retrospective 20,859 patients in Israel Lower hospitalization with vitamin D (p=0.0028) Israel et al., Epidemiology and Global.., Jul 2021 Favors vitamin D Favors control

Identification of drugs associated with reduced severity of COVID-19: A case-control study in a large population

Israel et al., Epidemiology and Global Health Microbiology and Infectious Disease, doi:10.7554/eLife.68165
Jul 2021  
  Source   PDF   All   Meta
Vitamin D for COVID-19
8th treatment shown to reduce risk in October 2020
*, now known with p < 0.00000000001 from 120 studies, recognized in 8 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,100+ studies for 60+ treatments.
Case control study examining medication usage with a healthcare database in Israel, showing lower risk of hospitalization with vitamin D (defined as being picked up within 35 days prior to PCR+). Other patients may have acquired vitamin D supplements outside of the healthcare system.
This is the 44th of 120 COVID-19 controlled studies for vitamin D, which collectively show efficacy with p<0.0000000001 (1 in 248 sextillion).
29 studies are RCTs, which show efficacy with p=0.0000024.
Study covers vitamin D and zinc.
risk of hospitalization, 13.1% lower, OR 0.87, p = 0.003, treatment 737 of 6,953 (10.6%) cases, 1,669 of 13,906 (12.0%) controls, NNT 33, case control OR, PCR+, cohort 2.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Israel et al., 27 Jul 2021, retrospective, Israel, peer-reviewed, 10 authors, dosage not specified.
This PaperVitamin DAll
Identification of drugs associated with reduced severity of COVID-19 – a case-control study in a large population
Ariel Israel, Alejandro A Schäffer, Assi Cicurel, Kuoyuan Cheng, Sanju Sinha, Eyal Schiff, Ilan Feldhamer, Ameer Tal, Gil Lavie, Eytan Ruppin
eLife, doi:10.7554/elife.68165
Background: Until coronavirus disease 2019 (COVID-19) drugs specifically developed to treat COVID-19 become more widely accessible, it is crucial to identify whether existing medications have a protective effect against severe disease. Toward this objective, we conducted a large population study in Clalit Health Services (CHS), the largest healthcare provider in Israel, insuring over 4.7 million members. Methods: Two case-control matched cohorts were assembled to assess which medications, acquired in the last month, decreased the risk of COVID-19 hospitalization. Case patients were adults aged 18 to 95 hospitalized for COVID-19. In the first cohort, five control patients, from the general population, were matched to each case (n=6202); in the second cohort, two nonhospitalized SARS-CoV-2 positive control patients were matched to each case (n=6919). The outcome measures for a medication were: odds ratio (OR) for hospitalization, 95% confidence interval (CI), and the p-value, using Fisher's exact test. False discovery rate was used to adjust for multiple testing. Results: Medications associated with most significantly reduced odds for COVID-19 hospitalization include: ubiquinone (OR=0.185, 95% CI [0.058 to 0.458], p<0.001), ezetimibe (OR=0.488, 95% CI [0.377 to 0.622], p<0.001), rosuvastatin (OR=0.673, 95% CI [0.596 to 0.758], p<0.001), flecainide (OR=0.301, 95% CI [0.118 to 0.641], p<0.001), and vitamin D (OR=0.869, 95% CI [0.792 to 0.954], p<0.003). Remarkably, acquisition of artificial tears, eye care wipes, and several ophthalmological products were also associated with decreased risk for hospitalization. Conclusions: Ubiquinone, ezetimibe, and rosuvastatin, all related to the cholesterol synthesis pathway were associated with reduced hospitalization risk. These findings point to a promising protective effect which should be further investigated in controlled, prospective studies.
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication. Additional files Author contributions Supplementary files . Source code 1. R source code, producing Figure 1 . . Supplementary file 1. Supplementary tables and figures. Suppl Tab 1 Multivariable logistic regression for hospitalization status according to ethnicity and medication consumption in Cohort 1. Suppl Tab 2 Multivariable logistic regression for hospitalization status according to ethnicity and medication consumption in Cohort 2. Figure supplements Forest plot showing association between drug use and hospitalization risk in each of the cohorts, divided by body mass index (BMI) category. Data availability Data were obtained from patients' electronic health records, and IRB approval restrains its use to researchers inside Clalit Health Services. For further information regarding data availability, researchers may contact Dr. Lavie This study is based on real-world patient drug purchases, and it cannot be made available due to patient privacy concerns. R code used to produce Figure 1 is available as a supplementary file named 'Source code 1'.
Aizaki, Morikawa, Fukasawa, Hara, Inoue et al., Critical role of virion-associated cholesterol and sphingolipid in hepatitis C virus infection, Journal of Virology, doi:10.1128/JVI.02530-07
Antonelli, Feldman, Freedberg, Darawsha, Rosenfeld, Intravenous flecainide administration for conversion of paroxysmal atrial fibrillation in the emergency room, Harefuah
Bajimaya, Hayashi, Frankl, Bryk, Ward et al., Cholesterol reducing agents inhibit assembly of type I parainfluenza viruses, Virology, doi:10.1016/j.virol.2016.11.011
Benjamini, Hochberg, Controlling the false discovery rate: a practical and powerful approach to multiple testing, Journal of the Royal Statistical Society: Series B
Bramante, Buse, Tamaritz, Palacio, Cohen et al., Outpatient metformin use is associated with reduced severity of COVID-19 disease in adults with overweight or obesity, Journal of Medical Virology, doi:10.1002/jmv.26873
Buhaescu, Izzedine, Mevalonate pathway: a review of clinical and therapeutical implications, Clinical Biochemistry, doi:10.1016/j.clinbiochem.2007.03.016
Ci, Postema, Arbelo, Behr, Bezzina et al., SARS-CoV-2, COVID-19, and inherited arrhythmia syndromes, Hear Rhythm, doi:10.1016/j.hrthm.2020.03.024
Dagliati, Malovini, Tibollo, Bellazzi, Health informatics and EHR to support clinical research in the COVID-19 pandemic: an overview, Briefings in Bioinformatics, doi:10.1093/bib/bbaa418
Estiri, Strasser, Klann, Naseri, Wagholikar et al., Predicting COVID-19 mortality with electronic medical records, Npj Digital Medicine, doi:10.1038/s41746-021-00383-x
Gower, Graham, Antiviral activity of lovastatin against respiratory syncytial virus in vivo and in vitro, Antimicrobial Agents and Chemotherapy, doi:10.1128/AAC.45.4.1231-1237.2001
Iroegbu, Ifenatuoha, Ijomone, Potential neurological impact of coronaviruses: implications for the novel SARS-CoV-2, Neurological Sciences, doi:10.1007/s10072-020-04469-4
Israel, Cicurel, Feldhamer, Dror, Giveon et al., The link between vitamin D deficiency and Covid-19 in a large population, medRxiv, doi:10.1101/2020.09.04.20188268
Kim, Ta, Liu, Sung, Butler et al., Towards clinical data-driven eligibility criteria optimization for interventional COVID-19 clinical trials, Journal of the American Medical Informatics Association, doi:10.1093/jamia/ocaa276
Koren, Shlezinger, Katz, Shalev, Amitai, Seawater desalination and serum magnesium concentrations in israel, Journal of Water and Health, doi:10.2166/wh.2016.164
Meinhardt, Radke, Dittmayer, Franz, Thomas et al., Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19, Nature Neuroscience, doi:10.1038/s41593-020-00758-5
Merzon, Tworowski, Gorohovski, Vinker, Cohen et al., Low plasma 25(OH) vitamin D level is associated with increased risk of covid-19 infection: an israeli population-based study, The FEBS Journal, doi:10.1111/febs.15495
Morales, Conover, You, Pratt, Kostka et al., Renin-angiotensin system blockers and susceptibility to COVID-19: an international, open science, cohort analysis, The Lancet Digital Health, doi:10.1016/S2589-7500(20)30289-2
Muhsen, Lapidot, Goren, Amir, Perlman et al., A nationwide analysis of population group differences in the COVID-19 epidemic in Israel, The Lancet Regional Health -Europe, doi:10.1016/j.lanepe.2021.100130
Osborne, Veigulis, Arreola, ¨o ¨sli, Curtin, Automated EHR score to predict COVID-19 outcomes at US department of veterans affairs, PLOS ONE, doi:10.1371/journal.pone.0236554
Osuna-Ramos, Reyes-Ruiz, ´ngel, The role of host cholesterol during Flavivirus infection, Frontiers in Cellular and Infection Microbiology, doi:10.3389/fcimb.2018.00388
Qu, Guo, Chai, Wang, Gao et al., Effects of coenzyme Q10 on Statin-Induced myopathy: an updated Meta-Analysis of randomized controlled trials, Journal of the American Heart Association, doi:10.1161/JAHA.118.009835
Ragan, Hartson, Pidcoke, Bowen, Goodrich, Pathogen reduction of SARS-CoV-2 virus in plasma and whole blood using Riboflavin and UV light, PLOS ONE, doi:10.1371/journal.pone.0233947
Rossman, Jing, Leser, Balannik, Pinto et al., Influenza virus m2 ion channel protein is necessary for filamentous virion formation, Journal of Virology, doi:10.1128/JVI.00119-10
Shadmi, Balicer, Kinder, Abrams, Weiner, Assessing socioeconomic health care utilization inequity in Israel: impact of alternative approaches to morbidity adjustment, BMC Public Health, doi:10.1186/1471-2458-11-609
Song, Zhang, Israelow, Lu-Culligan, Prado et al., Neuroinvasion of SARS-CoV-2 in human and mouse brain, Journal of Experimental Medicine, doi:10.1084/jem.20202135
Sudat, Robinson, Mudiganti, Mani, Pressman, Mind the clinical-analytic gap: electronic health records and COVID-19 pandemic response, Journal of Biomedical Informatics, doi:10.1016/j.jbi.2021.103715
Sun, Whittaker, Role for influenza virus envelope cholesterol in virus entry and infection, Journal of Virology, doi:10.1128/JVI.77.23.12543-12551.2003
Trasino, A role for retinoids in the treatment of COVID-19?, Clinical and Experimental Pharmacology and Physiology, doi:10.1111/1440-1681.13354
Tsoumpra, Muniz, Barnett, Kwaasi, Pilka et al., The inhibition of human farnesyl pyrophosphate synthase by nitrogen-containing bisphosphonates. Elucidating the role of active site threonine 201 and tyrosine 204 residues using enzyme mutants, Bone, doi:10.1016/j.bone.2015.08.020
Uwitonze, Razzaque, Role of magnesium in vitamin D activation and function, The Journal of the American Osteopathic Association, doi:10.7556/jaoa.2018.037
Wagner, Shweta, Murugadoss, Awasthi, Venkatakrishnan et al., Augmented curation of clinical notes from a massive EHR system reveals symptoms of impending COVID-19 diagnosis, eLife, doi:10.7554/eLife.58227
Wessels, Rolles, Rink, The potential impact of zinc supplementation on COVID-19 pathogenesis, Frontiers in Immunology, doi:10.3389/fimmu.2020.01712
Whitehorn, Nguyen, Khanh, Kien, Quyen et al., Lovastatin for the treatment of adult patients with dengue: a randomized, Double-Blind, Placebo-Controlled trial, Clinical Infectious Diseases, doi:10.1093/cid/civ949
Yavuz, Ertugrul, Cil, Ata, Akin et al., Increased levels of 25 hydroxyvitamin D and 1,25-dihydroxyvitamin D after rosuvastatin treatment: a novel pleiotropic effect of statins?, Cardiovascular Drugs and Therapy, doi:10.1007/s10557-009-6181-8
Yavuz, Ertugrul, Statins and vitamin D: a hot topic that will be discussed for a long time, Dermato-Endocrinology, doi:10.4161/derm.20188
Zeng, Wang, Li, Yang, Qiu et al., Association of daily wear of eyeglasses with susceptibility to coronavirus disease 2019 infection, JAMA Ophthalmology, doi:10.1001/jamaophthalmol.2020.3906
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop